SAN DIEGO, June 06, 2025 (GLOBE NEWSWIRE) -- Robbins LLP reminds stockholders that a class action was filed on behalf of investors who purchased or otherwise acquired Reckitt Benckiser Group PLC (OTC: RBGLY) American Depository Shares (ADSs) between January 13, 2021 and July 28, 2024. Reckitt is a United Kingdom-based global consumer goods company that reports three operating segments: Hygiene, Health, and Nutrition.
NEW YORK, June 06, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Reckitt Benckiser Group Plc (“Reckitt” or the “Company”)(OTC: RBGLY). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Reckitt Benckiser Group plc (“Reckitt” or “the Company”) (OTC: RBGLY) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action on behalf of purchasers of American Depositary Shares (“ADSs”) of Reckitt Benckiser Group PLC (OTC: RBGLY) between January 13, 2021 through July 28, 2024. Reckitt describes itself as a “U.K.-based consumer goods and health conglomerate.”
Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until August 4, 2025 to file lead plaintiff applications in a securities class action lawsuit against Reckitt Benckiser Group PLC (“Reckitt” or the “Company”) (OTC: RBGLY), if they purchased the Company’s American Depositary Shares (“ADSs”) between January 13, 2021 and July 28, 2024, inclusive (the “Class Period”). This action is pending in the United States District Court for the Southern District of New York.
Scott+Scott Attorneys at Law LLP (“Scott+Scott”), an international shareholder and consumer rights litigation firm, has filed a securities class action lawsuit in the United States District Court for the Southern District of New York against Reckitt Benckiser Group PLC (“Reckitt” or the “Company”) (OTC: RBGLY), and certain of its former and current officers and/or directors (collectively, “Defendants”). The Class Action asserts claims under §§10(b) and 20(a) of the Securities Exchange Act of 1934 (15 U.S.C. §§78j(b) and 78t(a)) and U.S. Securities and Exchange Commission Rule 10b-5 promulgated thereunder (17 C.F.R. §240.10b‑5) on behalf of all persons other than Defendants who purchased or otherwise acquired Reckitt American Depositary Shares (“ADSs”) between January 13, 2021, and July 28, 2024, inclusive (the “Class Period”), and were damaged thereby (the “Class”). The Class Action filed by Scott+Scott is captioned: Elevator Constructors Union Local No. 1 Annuity & 401(K) Fund v. Reckitt Benckiser Group PLC, et al., Case No. 1:25-cv-4708.
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Reckitt Benckiser Group plc (“Reckitt” or “the Company”) (OTC: RBGLY) for violations of the securities laws.
Scott+Scott Attorneys at Law LLP (“Scott+Scott”), a shareholder and consumer rights litigation firm, is investigating whether Reckitt Benckiser Group PLC (“Reckitt” or the “Company”) (OTC: RBGLY) or certain of its officers and directors issued misleading and false statements, and/or failed to disclose information material to investors in violation of federal securities laws.
FDA proposes removing oral phenylephrine from OTC drugs for nasal congestion, citing ineffectiveness. Public comments open before a final order is issued.
Piper Sandler initiates coverage on Abbott with an Overweight rating, citing its diversified business model, strong medtech growth and attractive valuation.
Reckitt Benckiser is reportedly in early talks to sell its homecare division, featuring brands like Air Wick and Calgon, as part of a broader strategy to focus on consumer health and hygiene. The sale could be valued at over £6 billion.
This verdict is part of nearly 1,000 lawsuits filed against Abbott Labs, its British rival Reckitt Benckiser, or both, in U.S. federal or state courts.
Abbott faces trial over claims its baby formula causes necrotizing enterocolitis in preterm infants. This is the second trial among hundreds of similar lawsuits, impacting Abbott and Reckitt Benckiser.
An Illinois jury orders Reckitt Benckiser's Mead Johnson to pay $60 million after a premature infant's tragic death linked to Enfamil baby formula. Mead Johnson found negligent for not warning about NEC risks. Over 400 NEC lawsuits pending in federal court in Chicago.
Reckitt Benckiser Group is leveraging the popularity of livestream shopping in China to sell condoms, a move that could be challenging due to strict regulatory oversight.
A massive recall of hypoallergenic infant formula has been initiated due to concerns over potential bacteria contamination. The recall involves approximately 675,000 cans of infant formula.
According to FDA panel experts who reviewed the latest research on the long-questioned phenylephrine, a drug ingredient used in several leading decongestants used by millions of Americans looking for relief from
